Results 111 to 120 of about 14,520 (202)

Oestrogen receptors regulate vascular β₁- and β₃-adrenoceptor expression and shape sex-specific adrenergic control of vascular tone. [PDF]

Pflugers Arch
Riedel K, Deussen A, Zatschler B, Hentsche C, Müller B, Speier S, Reeps C, Tugtekin SM, Matschke K, Kopaliani I.   +9 more
europepmc   +1 more source

Capivasertib as a Therapeutic Agent for Breast Cancer: Targeting AKT to Overcome Endocrine Resistance. [PDF]

J Clin Med
Damaskos C, Garmpis N, Arkadopoulos N, Michalopoulos NV, Garmpi A, Papandroudis MP, Effraimidou EI.   +6 more
europepmc   +1 more source

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer. [PDF]

ESMO Open
Im SA, Kalinsky K, Jhaveri KL, Loibl S, Turner N, Saura C, Schmid P, Loi S, Hamilton E, Karadurmus N, Wang S, Awan AA, Ciruelos EM, Chung CF, Thanopoulou E, Shankar N, Lim S, Jin Y, Song C, Juric D.   +19 more
europepmc   +1 more source

SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under Hyperglycemia. [PDF]

Int J Mol Sci
Quagliariello V, Berretta M, Barbato M, Maurea F, Canale ML, Paccone A, Bisceglia I, Tedeschi A, Scherillo M, Santagata J, Oliva S, Dessalvi CC, Forte P, D'Ambrosio C, Matola TD, Parmentola R, Gabrielli D, Maurea N.   +17 more
europepmc   +1 more source

Beyond CDK4/6 Inhibition: Current Strategies in Hormone Receptor-Positive Metastatic Breast Cancer. [PDF]

Curr Treat Options Oncol
Cetin B, Erdem D, Karaman I, Gumusay O.
europepmc   +1 more source

Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer-comparing real-world outcomes in England to the MONARCH-2 trial. [PDF]

Br J Cancer
Anderson J, Lawton S, Thackray K, Kipps E.   +3 more
europepmc   +1 more source

The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models. [PDF]

Mol Cancer Ther
Ma J, Hegde S, Sergeeva M, Chakraborty B, Wardell SE, McDonnell DP, Huang PQ, Bunker KD, Doñate F, Lackner MR, Samatar AA.   +10 more
europepmc   +1 more source

Comparative effectiveness of CDK4/6 inhibitor plus endocrine therapy combinations in HR-positive, HER2-negative metastatic breast cancer: the inspiration 01 study. [PDF]

Front Pharmacol
Jia Y, Zhang J, Wang X, Hao C, Wang C, Li S, Lu N, Dong G, Zhao W, Jia Y, Huang L, Gu J, Shi Y, Tong Z.   +13 more
europepmc   +1 more source

Subsequent Treatments After Progression on Cyclin-Dependent Kinase 4/6 Inhibitors: A Review of the Evidence and a Real-World Data Perspective From Portuguese Hospitals. [PDF]

Cureus
Freitas R, Barroso T, Braga S, Santos CC, Batista M, Chaves A, Cabral S, Fortuna A, Patel V, Araújo J, Duarte T, Cabral TP, Silva S, Viana C, Baptista C, Gonçalves J, Dunões IQ, Eiriz I.   +17 more
europepmc   +1 more source

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials. [PDF]

ESMO Open
Jhaveri K, Bidard FC, Kalinsky K, Neven P, Rugo HS, Tolaney SM, Litchfield LM, von Laue CC, Traore S, Sapunar F, Li Y, O'Shaughnessy J.   +11 more
europepmc   +1 more source